Advancements in research and clinical management of interstitial lung injury associated with ADC drugs administration in breast cancer
Abstract Antibody–drug conjugates (ADCs) represent a novel class of targeted anti-tumor medications that utilize the covalent linkage between monoclonal antibodies and cytotoxic agents. This unique mechanism combines the cytotoxic potency of drugs with the targeting specificity conferred by antigen...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2024-12-01
|
| Series: | Discover Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s12672-024-01705-7 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846101032752381952 |
|---|---|
| author | Jia-yu Zhu Rui-yuan Jiang Huan-ping Zhang Zi-ru Fang Huan-huan Zhou Qing Wei Xiaojia Wang |
| author_facet | Jia-yu Zhu Rui-yuan Jiang Huan-ping Zhang Zi-ru Fang Huan-huan Zhou Qing Wei Xiaojia Wang |
| author_sort | Jia-yu Zhu |
| collection | DOAJ |
| description | Abstract Antibody–drug conjugates (ADCs) represent a novel class of targeted anti-tumor medications that utilize the covalent linkage between monoclonal antibodies and cytotoxic agents. This unique mechanism combines the cytotoxic potency of drugs with the targeting specificity conferred by antigen recognition. However, it is essential to recognize that many ADCs still face challenges related to off-target toxicity akin to cytotoxic payloads, as well as targeted toxicity and other potential life-threatening adverse effects, such as treatment-induced interstitial lung injury. Currently, of the four approved ADC drugs for breast cancer, several reports have documented post-treatment lung injury-related fatalities. As a result, treatment-induced interstitial lung injury due to ADC drugs has become a clinical concern. In this review article, we delve into the factors associated with ADC-induced interstitial lung injury in patients with advanced-stage breast cancer and highlight strategies expected to decrease the incidence of ADC-related interstitial lung injury in the years ahead. These efforts are directed at enhancing treatment outcomes in both advanced and early-stage cancer patients while also providing insights into the development and innovation of ADC drugs and bolstering clinicians’ understanding of the diagnosis and management of ADC-associated interstitial lung injury. |
| format | Article |
| id | doaj-art-2d5024f6917a4c3997672e64d35f79ad |
| institution | Kabale University |
| issn | 2730-6011 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Springer |
| record_format | Article |
| series | Discover Oncology |
| spelling | doaj-art-2d5024f6917a4c3997672e64d35f79ad2024-12-29T12:37:49ZengSpringerDiscover Oncology2730-60112024-12-0115112010.1007/s12672-024-01705-7Advancements in research and clinical management of interstitial lung injury associated with ADC drugs administration in breast cancerJia-yu Zhu0Rui-yuan Jiang1Huan-ping Zhang2Zi-ru Fang3Huan-huan Zhou4Qing Wei5Xiaojia Wang6Department of Graduate Student, Zhejiang Chinese Medical UniversityDepartment of Graduate Student, Zhejiang Chinese Medical UniversityDepartment of Graduate Student, Zhejiang Chinese Medical UniversityDepartment of Graduate Student, Zhejiang Chinese Medical UniversityZhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of SciencesZhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of SciencesZhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of SciencesAbstract Antibody–drug conjugates (ADCs) represent a novel class of targeted anti-tumor medications that utilize the covalent linkage between monoclonal antibodies and cytotoxic agents. This unique mechanism combines the cytotoxic potency of drugs with the targeting specificity conferred by antigen recognition. However, it is essential to recognize that many ADCs still face challenges related to off-target toxicity akin to cytotoxic payloads, as well as targeted toxicity and other potential life-threatening adverse effects, such as treatment-induced interstitial lung injury. Currently, of the four approved ADC drugs for breast cancer, several reports have documented post-treatment lung injury-related fatalities. As a result, treatment-induced interstitial lung injury due to ADC drugs has become a clinical concern. In this review article, we delve into the factors associated with ADC-induced interstitial lung injury in patients with advanced-stage breast cancer and highlight strategies expected to decrease the incidence of ADC-related interstitial lung injury in the years ahead. These efforts are directed at enhancing treatment outcomes in both advanced and early-stage cancer patients while also providing insights into the development and innovation of ADC drugs and bolstering clinicians’ understanding of the diagnosis and management of ADC-associated interstitial lung injury.https://doi.org/10.1007/s12672-024-01705-7Antibody–drug conjugateBreast cancerTargeted therapyAdverse reactionDrug-induced interstitial lung injury |
| spellingShingle | Jia-yu Zhu Rui-yuan Jiang Huan-ping Zhang Zi-ru Fang Huan-huan Zhou Qing Wei Xiaojia Wang Advancements in research and clinical management of interstitial lung injury associated with ADC drugs administration in breast cancer Discover Oncology Antibody–drug conjugate Breast cancer Targeted therapy Adverse reaction Drug-induced interstitial lung injury |
| title | Advancements in research and clinical management of interstitial lung injury associated with ADC drugs administration in breast cancer |
| title_full | Advancements in research and clinical management of interstitial lung injury associated with ADC drugs administration in breast cancer |
| title_fullStr | Advancements in research and clinical management of interstitial lung injury associated with ADC drugs administration in breast cancer |
| title_full_unstemmed | Advancements in research and clinical management of interstitial lung injury associated with ADC drugs administration in breast cancer |
| title_short | Advancements in research and clinical management of interstitial lung injury associated with ADC drugs administration in breast cancer |
| title_sort | advancements in research and clinical management of interstitial lung injury associated with adc drugs administration in breast cancer |
| topic | Antibody–drug conjugate Breast cancer Targeted therapy Adverse reaction Drug-induced interstitial lung injury |
| url | https://doi.org/10.1007/s12672-024-01705-7 |
| work_keys_str_mv | AT jiayuzhu advancementsinresearchandclinicalmanagementofinterstitiallunginjuryassociatedwithadcdrugsadministrationinbreastcancer AT ruiyuanjiang advancementsinresearchandclinicalmanagementofinterstitiallunginjuryassociatedwithadcdrugsadministrationinbreastcancer AT huanpingzhang advancementsinresearchandclinicalmanagementofinterstitiallunginjuryassociatedwithadcdrugsadministrationinbreastcancer AT zirufang advancementsinresearchandclinicalmanagementofinterstitiallunginjuryassociatedwithadcdrugsadministrationinbreastcancer AT huanhuanzhou advancementsinresearchandclinicalmanagementofinterstitiallunginjuryassociatedwithadcdrugsadministrationinbreastcancer AT qingwei advancementsinresearchandclinicalmanagementofinterstitiallunginjuryassociatedwithadcdrugsadministrationinbreastcancer AT xiaojiawang advancementsinresearchandclinicalmanagementofinterstitiallunginjuryassociatedwithadcdrugsadministrationinbreastcancer |